Efficacy comparison of 9 chemotherapy regimens in nonmetastatic Ewing’s sarcoma treatment: A network meta-analysis

BACKGROUND: Optimal chemotherapy for nonmetastatic Ewing's sarcoma (ES) remains undefined, with no global consensus established among the available multidrug regimens. METHODS: We systematically searched PubMed, Embase, Cochrane Library, and Chinese databases (VIP [Chinese Scientific Journal Database], WanFang, China National Knowledge Infrastructure) up to May 2024 for randomized controlled trials (RCTs) and cohort studies comparing chemotherapy regimens for nonmetastatic ES. Risk of bias was evaluated using Cochrane tools (for RCTs) and the Newcastle-Ottawa Scale (for cohort studies). Efficacy was ranked via surface under the cumulative ranking curve (SUCRA) values for event-free survival and overall survival. RESULTS: Twelve studies (3834 patients) evaluating 9 regimens were included. The top 3 regimens for event-free survival were as follows: VDC (vincristine/doxorubicin/cyclophosphamide) + IE (ifosfamide/etoposide)(In)(intensified regimen) and VTC (vincristine, topotecan, cyclophosphamide) (SUCRA = 92.1%); VDC+IE(In) (SUCRA = 85.4%); VDC+IE(St)(standard regimen) (SUCRA = 79.2%). For overall survival, the ranking was similar. VDC alone ranked lowest in both outcomes. CONCLUSION: The VDC+IE(In)+VTC combination may exhibit superior efficacy among the 9 chemotherapy regimens for nonmetastatic ES, necessitating further validation through RCTs with larger sample sizes.

Authors

Institutions

Publication Details

Journal
Medicine
Published
2026-11-13
DOI
https://doi.org/10.1097/md.0000000000047464
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Efficacy comparison of 9 chemotherapy regimens in nonmetastatic Ewing’s sarcoma treatment: A network meta-analysis

Zhong‐Liang Deng, Yi Yu, Xiaohua Zhang, Jinwei Guo et al.
Medicine
Sarcoma Diagnosis and Treatment
article

Efficacy comparison of 9 chemotherapy regimens in nonmetastatic Ewing’s sarcoma treatment: A network meta-analysis

Zhong‐Liang Deng, Yi Yu, Xiaohua Zhang, Jinwei Guo, Jian Xu, Xin Zhou, Jialin Deng
article en

Abstract

BACKGROUND: Optimal chemotherapy for nonmetastatic Ewing's sarcoma (ES) remains undefined, with no global consensus established among the available multidrug regimens. METHODS: We systematically searched PubMed, Embase, Cochrane Library, and Chinese databases (VIP [Chinese Scientific Journal Database], WanFang, China National Knowledge Infrastructure) up to May 2024 for randomized controlled trials (RCTs) and cohort studies comparing chemotherapy regimens for nonmetastatic ES. Risk of bias was evaluated using Cochrane tools (for RCTs) and the Newcastle-Ottawa Scale (for cohort studies). Efficacy was ranked via surface under the cumulative ranking curve (SUCRA) values for event-free survival and overall survival. RESULTS: Twelve studies (3834 patients) evaluating 9 regimens were included. The top 3 regimens for event-free survival were as follows: VDC (vincristine/doxorubicin/cyclophosphamide) + IE (ifosfamide/etoposide)(In)(intensified regimen) and VTC (vincristine, topotecan, cyclophosphamide) (SUCRA = 92.1%); VDC+IE(In) (SUCRA = 85.4%); VDC+IE(St)(standard regimen) (SUCRA = 79.2%). For overall survival, the ranking was similar. VDC alone ranked lowest in both outcomes. CONCLUSION: The VDC+IE(In)+VTC combination may exhibit superior efficacy among the 9 chemotherapy regimens for nonmetastatic ES, necessitating further validation through RCTs with larger sample sizes.

MedicineVol. 105(46)
Chongqing University (CN), Dalian Medical University (CN), Second Affiliated Hospital of Chongqing Medical University (CN), Jiangjin Central Hospital (CN), Chongqing Medical University (CN)
Good health and well-being
Sarcoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon